Table 1 Overview patients treated with pazopanib and sunitinib
Pt | Localization | Prior local Tx | Prior systemic Tx | Drug/dose | Results (RECIST 1.1 criteria) | Adverse events |
|---|---|---|---|---|---|---|
1 | Sacrum | Intralesional excision + cryosurgery Adjuvant radiotherapy | – | Pazopanib 600 mg/day | SD 14 months Symptomatic improvement | Rash gr 1, intermittent diarrhoea max gr 2, fatigue gr 2, loss pigment hair |
2 | Sacrum | – | – | Pazopanib 800 mg/day | SD 15 months Symptomatic improvement | Fatigue gr 1 |
3 | Sacrum | En-bloc resection (adequate margins) | – | Pazopanib 800 mg/day | PD 3 months | Intermittent nausea and vomiting gr 1 |
4 | Thoracic spine | Intralesional excision 3x Stereotactic radiotherapy after 1st surgery | Imatinib | Pazopanib 800 mg/day | PD 3 months, paraplegia | – |
5 | Lumbar spine | Intralesional excision 3x Adjuvant radiotherapy after 2nd surgery | Imatinib | Sunitinib 37.5 mg/day | Radiologic response (PR) 3 months SD 27 months Symptomatic improvement | Dose reduction due to gr 2 nausea. Other symptoms: intermittent fatigue gr 2, hand-foot syndrome gr 1, epistaxis gr 1, thrombocytopenia gr 2 |